• Anti-Epileptic Drugs and Human PON1 Inhibition

  2026-08-26

  The reference study examined how five commonly used antiepileptic drugs inhibit purified human serum paraoxonase-1 (hPON1) in vitro. Phenytoin showed weaker inhibition than gabapentin, valproic acid, and primidone but stronger inhibition than levetiracetam, while all tested compounds were classified as noncompetitive inhibitors.

• SU 5402 Workflows for RTK and Neuronal Models

  2026-08-26

  SU 5402 provides a practical way to perturb VEGFR2, FGFR1, and PDGFRβ signaling across phosphorylation, viability, apoptosis, and cell-cycle assays. This guide translates its cancer biology applications into a carefully bounded strategy for studying signaling in human iPSC-derived sensory neurons and HSV-1 latency models.

• Berberine hydrochloride in Gut–Bone Research

  2026-08-25

  Berberine hydrochloride provides a practical entry point for connecting intestinal microbiota, tuft-cell biology, immune balance, and bone-resorption assays. This workflow translates a recent gut–bone study into reproducible preparation, organoid, microbiome, metabolic, and troubleshooting strategies.

• PDGF-BB in Pulmonary Hypertension Assays

  2026-08-25

  Build reproducible proliferation and signaling workflows with murine recombinant PDGF-BB, from dose-response testing to pulmonary artery smooth muscle cell models. This guide connects a defined mitogenic stimulus with the ALDOB lactylation–mitochondrial fission framework reported in pulmonary hypertension research.

• AEBSF.HCl: Practical Protease Workflows

  2026-08-24

  AEBSF.HCl provides irreversible, broad-spectrum serine protease control for lysate protection, APP-processing studies, and cell-lysis assays. This guide also clarifies where it complements necroptosis experiments—and why it should not be treated as a direct cathepsin B inhibitor.

• Fludarabine Workflows for Tumor Antigen Studies

  2026-08-24

  Fludarabine combines direct DNA synthesis inhibition with a practical framework for separating tumor-cell apoptosis from immune-mediated killing. This guide translates recent antigen-presentation findings into dose-response, co-culture, and troubleshooting workflows for leukemia research, multiple myeloma research, and neoantigen-directed T-cell studies.

• Cefoperazone: From MIC Data to Model Design

  2026-08-23

  Explore how Cefoperazone sodium salt can be used to connect comparative susceptibility data with better antimicrobial assay and infection-model decisions. This evidence-centered guide covers β-lactamase stability, MIC/MBC interpretation, compound handling, and biliary tract infection research.

• Leucovorin Calcium in Tumor–Stroma Translation

  2026-08-22

  Leucovorin Calcium is more than a methotrexate rescue reagent: it is a mechanistic probe for testing how folate availability, tumor context, and stromal composition shape treatment response. This article connects calcium folinate biology with patient-derived gastric cancer assembloids and provides practical guidance for designing more informative translational assays.

• HyperFluor 488 Goat Anti-Rabbit IgG: Practical Guide

  2026-08-21

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody provides fluorescent detection of rabbit primary antibodies in immunofluorescence, microscopy, immunohistochemistry, immunocytochemistry, and flow-based workflows. It should be used only after confirming rabbit-primary compatibility and should not be treated as validated for non-rabbit primaries or untested applications without additional optimization.

• Bile Acid Subtypes Reveal Immune Dysfunction in CRC

  2026-08-20

  Feng et al. developed a bile acid metabolism-based molecular classification for colon adenocarcinoma and linked the bile-low subtype to shorter survival and altered immune-cell infiltration. The study further identified CLCA1, UGT2A3, and ZG16 as candidate markers for tumor biology, immune dysfunction, and biomarker-focused colorectal cancer research.

• PDHA1 Succinylation and Immune Escape in Cholangiocarcinoma

  2026-08-20

  The reference study defines a metabolic–immune pathway in which PDHA1 K83 succinylation increases PDH activity, promotes α-ketoglutarate accumulation, and suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling. Its findings connect tumor metabolic flux with chemotherapy resistance and suggest that inhibiting succinylation may improve gemcitabine–cisplatin responses, although clinical validation remains necessary.

• Sulforaphane, Oxidative Stress, and NLRP3 in Colitis

  2026-08-19

  A 2024 mouse study links sulforaphane-mediated reduction of reactive oxygen species with suppression of NLRP3 inflammasome signaling in dextran sodium sulfate-induced colitis. Its combined in vivo and macrophage-cell experiments provide a mechanistic framework for studying redox-sensitive intestinal inflammation while highlighting the limits of translating preclinical dosing to human disease.

• Alda 1 and ALDH2: From Aldehyde Detoxification to Repair

  2026-08-19

  Alda 1 is an ALDH2 activator that connects mitochondrial aldehyde detoxification with emerging strategies for cardioprotection, cardiac repair, and radiation-induced dermatitis mitigation. This thought-leadership article interprets recent evidence showing that ALDH2 activation can promote cardiomyocyte proliferation and delay pressure overload-induced heart failure, while outlining practical study-design principles, translational opportunities, and the limitations researchers should address before moving toward clinical development.

• Solanesol (B8776): Handling and QC Guide

  2026-08-18

  Solanesol (SKU B8776) provides a defined polyisoprenoid alcohol for workflows that require controlled handling of a hydrophobic research compound. It is suitable for selected biochemical and membrane-related studies when prepared in DMSO, but it should not be used in water- or ethanol-based preparations or in diagnostic and clinical workflows.

• Mcl-1 Super-Enhancer Targeting in Glioblastoma

  2026-08-18

  The reference study identifies a super-enhancer around Mcl-1 in glioblastoma and shows that its epigenetic disruption creates synthetic lethality with BCL-2/BCL-XL inhibition. The findings provide a mechanistic framework for apoptosis induction via BCL-XL inhibition while highlighting the model dependence and translational challenges of this combination strategy.

8537 records 1/570 page Next 12345 下5页 Last page